Article metrics

Original research
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

 

Online download statistics by month:

Online download statistics by month: October 2021 to May 2022

AbstractFullPdf
Oct 202111841194369
Nov 2021674675187
Dec 202120920978
Jan 202220921480
Feb 202211811958
Mar 202218618748
Apr 202211711947
May 202212112655
Total28182843922